Lakewood, CO, United States
Lakewood, CO, United States

Gambro is a global medical technology companythat manufactures products for Dialysis treatment.The company is a global leader in developing, manufacturing andsupplying products and therapies for Kidneyand Liver Dialysis, Myeloma Kidney Therapy, and otherextracorporeal therapies for Chronic and Acute patients.Gambro was founded in Lund, Sweden in 1964 by HolgerCrafoord and has approx. 8,000 employees, productionfacilities in 9 countries, and sales in more than100 countries. In September 2013, Baxter Intl. completed its acquisition of Gambro. Wikipedia.


Time filter

Source Type

Patent
Gambro | Date: 2016-11-17

An apparatus for extracorporeal blood treatment, comprising a treatment unit (2) having a first chamber (3) and a second chamber (4) separated from one another by a semipermeable membrane (5), a blood removal line (6) connected in inlet with the first chamber (3) and a blood return line (7) connected in outlet with the first chamber; an infusion line (9; 9a, 9b) of a replacement fluid and a fluid evacuation line (10) connected in outlet from the second chamber. A regulating device (20) of a transmembrane pressure is active on at least one of the lines and a control unit (15) is configured to: command the regulating device (20) by setting a first increase (TMP_(1)), determine a value of a control parameter (_(1)) corresponding to the first increase, compare the value of the control parameter (_(1)) with a reference value (_(ref)) and, if the value of the control parameter is greater than the reference value, command the regulating device (20) by setting a second increase (TMP_(2)) which is greater than the first increase (TMP_(1)).


A method of treating blood withdrawn from patient including: simultaneously withdrawing blood and infusing withdrawn blood from and to the patient by flowing the withdrawn blood through an extracorporeal dialysis circuit including a dialyzer having a semi-permeable dialysis membrane and a dialysate side adjacent the membrane; feeding a dialysate containing 1 to 5 mM total calcium and 2 to 8 mM citrate to the dialysate side of the dialyzer, and introducing an anticoagulation fluid including at least 8 mM citrate into the


A user interface for a machine for extracorporeal blood treatment comprises a touch screen and a controller programmed to display on a screen (16) a display in which two distinct areas are arranged, one of which (161) exhibits a series of touch keys (17). Activation of any one touch key (17) causes visualization of an image in a second area (162) of the screen. The images are displayed alternatively and are at least partly different one from another. Each touch key (17) is associated to an instruction, or to a group of instructions, all concerned with readying the machine for use. Each image is a pictograph of a configuration of the machine, correlated with an instruction associated to the touch key (17) selected. The operator is aided in making the machine ready for treatment.


A method to form a dialysis composition includes determining for a patient a prescribed calcium concentration for a dialysis fluid to be administered to the patient. The determination is made based on a non-citrate containing calcium dialysis fluid. 0.5 to 3 mM citrate and 1 to 5 mM total calcium are introduced to the dialysis fluid. The total calcium results in a calcium concentration that is 0.1 to 0.2 mM per 1 mM citrate greater than the prescribed calcium concentration. 0 to 1.5 mM total magnesium is introduced to the dialysis fluid.


Patent
Gambro | Date: 2016-08-18

An apparatus for extracorporeal treatment of blood (1) comprising a filtration unit (2), a blood withdrawal line (6), a blood return line (7), an effluent fluid line (13), a pre and/or post-dilution fluid line (15, 25) connected to the blood withdrawal line, and a dialysis fluid line. Pumps (17, 18, 21, 22, 27) act on the fluid lines for regulating the flow of fluid. A control unit (10) is configured to periodically calculate a new value for the patient fluid removal rate to be imposed on an ultrafiltration actuator in order to keep a predefined patient fluid removal rate across a reference time interval irrespective of machine down times.


A method of monitoring the integrity of a fluid connection between first and second fluid containing systems based on at least one time-dependent measurement signal from a pressure sensor in the first fluid containing system. The pressure sensor detects first pulses originating from a first pulse generator in the first fluid containing system and second pulses originating from a second pulse generator in the second fluid containing system. A parameter value representing a distribution of signal values within a time window is calculated by analyzing the measurement signal in the time domain and/or by using information on the timing of the second pulses in the measurement signal. The parameter value may be calculated as a statistical dispersion measure of the signal values, or from matching the signal to a predicted temporal signal profile of the second pulse. The integrity of the fluid connection is determined from the parameter value.


Patent
Gambro | Date: 2016-06-29

The present invention relates to a continuous process for preparing permselective hollow fiber membranes being suitable e.g. for hemodialysis, hemodiafiltration and hemofiltration of blood which comprises a two-stage drying and tempering treatment of the hollow fiber membranes. According to a further aspect, the invention relates to a continuous process for drying permselective hollow fiber membranes on-line. The invention also relates to devices for on-line drying of permselective hollow fiber membranes.


The present invention relates to a medical solution. According to the invention the ready-for-use solution comprises phosphate in a concentration of 1.0 - 2.8 mM, is sterile and has a pH of 6.5-7.6. The present invention further relates to a method for producing the medical solution and the use thereof.


Patent
Gambro | Date: 2016-09-01

A dialysis acid precursor assembly including a dialysis acid precursor composition of dry components including anhydrous glucose, a dry acid, a magnesium chloride 4.5-hydrate (MgCl_(2).4.5H_(2)O) and a potassium salt or calcium salt, and a moisture-resistant container with a water vapor transmission rate less than 0.2 g/m^(2)/d at 38 C./90% RH, wherein the dialysis acid precursor composition is sealed within the container.


Patent
Gambro | Date: 2016-11-16

The present disclosure relates to a hemodialysis membrane for the treatment of hemolytic events, especially acute episodes of hemolysis which lead to elevated levels of plasma free hemoglobin. The present disclosure further relates to methods of removing hemoglobin from the blood of patients undergoing a hemolytic event. The treatment and method encompasses using a hemodialysis membrane which is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 15 and 20 kD and a MWCO of between 170-320 kD, or, in the alternative, has a MWRO of between 9 and 14 kD and a MWCO of between 55 kD and 130 kD.

Loading Gambro collaborators
Loading Gambro collaborators